Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Early Phase 1
1(33.3%)
3Total
N/A(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05811377Early Phase 1Completed

Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay

Role: lead

NCT04000763Not ApplicableCompleted

Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention

Role: lead

NCT01972061Not ApplicableTerminated

Foot/Hand Neuromodulation for Overactive Bladder (OAB)

Role: lead

All 3 trials loaded